However, given the need for new treatments for patients with IPF, drugs that modulate kynurenine pathway enzymes, i.e., TDO2, or AHR directly represent an exciting possibility with untapped therapeutic potential. This evidence concerns the gene TDO2 and idiopathic pulmonary fibrosis.